review back old water path
recoveri still question maintain underweight
report extrem disappoint result flat
organ growth far cri expect jpme especi given
unusu easi comp along signific ep miss vs
jpme/street despit share repo peak
look closer weak attribut greater-than-expect
macro impact china cc attribut crackdown local
gener manufactur expos vs peer
total sale highlight preview well on-going food ministri
reorgan headwind previous call agil
last year europ cc due brexit-rel caution slow
budget releas pharma industri custom heard
includ throughout much last year light
miss also significantli reduc guidanc top
bottom-lin call cc revenu growth vs cc
previous ep vs previous
step back dramat miss deep guidanc cut highli
disappoint make rebound brief especi consid
suppos year stepped-up growth last year
transient headwind fade new product ramp manag
remain confid improv year visibl path
recoveri remain low consid china gener pharma headwind
take time play new product bioaccord take multipl
quarter ramp saw similar purchas delay dynam last year
rebound seen new guidanc also cast long-
term outlook laid analyst day two month ago doubt
quarter bring back question abil revers share loss
drive growth reacceler face evolv competit landscap
see lc/m survey color
final stock current today vs gain
 still view valuat ntm ebitda ntm price-to-earnings
full given uncertain growth trajectori greater cyclic risk vs peer ta
quarter pll industri msd call
macro-driven slowdown limit room margin expans
although near-term worth note share could see
recoveri compani re-start buy-back alreadi buy stock today
accord follow-up call manag nonetheless remain
underweight adjust dec pt lower
reflect temper growth outlook
sourc style exposur morgan quantit deriv strategi tabl compani data morgan estim
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
summari invest thesi valuat
given near-peak margin structur unlik
improv meaning current level view
increas competit dynam believ name
within coverag univers present appeal risk-
reward could look becom construct
pullback compani still gener signific cash flow
highest oper margin within industri
continu endors high-roic invest
price target deriv dcf analysi
use termin growth wacc
million
cash-flow oper
margin growth
sourc perform driver bloomberg morgan quantit deriv strategi tabl compani data morgan estim
back old water massiv miss top bottom-lin
report revenu came significantli jpme/consensu
flat organ growth also far cri expect jpme
especi given unusu easi comp end market
perform weak pharma flat cc brief rebound last quarter
despit easi cc comp
cc
government/academ cc healthi segment region
weak seen across america flat cc europ cc asia cc
china note india saw solid msd growth although on-going
elect cycl still leav manag cautious optimist improv
trend bottom line ep also came well jpme/street
despit repurchas million share quarter
beg question whether buy stock back right
given lack visibl on-going execut challeng
guidanc also significantli reduc despit signific repo
given massiv miss compani significantli reduc
guidanc top bottom-lin call full-year revenu
growth cc vs cc previous ep rang
instrument sale throughout year base healthi quot activ
especi europ china also expect return sort
growth new product contribut well stabl growth recur
revenu ep outlook reflect lower gross margin expect
vs previous given slower top-lin growth despit
on-going buy-back compani expect cc growth
china europ expect see modest improv fx headwind
ep vs street assum share repurchas
quarter
maintain underweight lower pt overal dramat miss
deep guidanc cut highli disappoint make rebound seen
brief especi consid suppos year
stepped-up growth last year transient headwind fade new product
ramp manag remain confid improv year
visibl expect recoveri remain low view saw similar
purchas delay dynam last year rebound seen new
guidanc also cast doubt long-term outlook laid analyst
day two month ago quarter bring back question abil
revers share loss drive growth reacceler step back
stock current still view valuat ntm ebitda
ntm price-to-earnings full given uncertainti around futur growth trajectori
includ competit dynam outlin lc/m survey limit
room margin expans remain underweight adjust
dec pt vs previous reflect temper growth
compani report bloomberg morgan estim
invest thesi valuat risk
given near-peak margin structur unlik improv meaning
current level view increas competit dynam believ
name within coverag univers present appeal risk-reward could
look becom construct pullback compani still gener
signific cash flow highest oper margin within industri
continu endors high-roic invest
price target deriv dcf analysi use termin growth
wacc
risk rate price
upsid risk price target underweight rate includ greater-than-
anticip traction newer product well outsiz growth
lc ms servic
good sold
chang gross margin y/i bp
chang op margin y/i bp
pv termin valu
perpetu growth rate
enterpris valu
water summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif author name within report research analyst unless otherwis specifi research analyst
denot ac cover report certifi multipl research analyst primarili respons report
research analyst denot ac cover within document individu certifi respect secur issuer
research analyst cover research view express report accur reflect person view
subject secur issuer part research analyst compens
directli indirectli relat specif recommend view express research analyst report korea-
base research analyst list front cover also certifi per kofia requir analysi made good faith
view reflect opinion without undu influenc intervent
